UBS raised the firm’s price target on BrightSpring Health (BTSG) to $30 from $22 and keeps a Buy rating on the shares. BrightSpring has seen more than 25% growth in oncology with no signs of slowing due to the $90B of new drugs expected to come to the market over the next 7-9 years, which will create a continual flow of innovative new brands coming to the market where the company is winning the right to dispense 10-15 of these each year, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BTSG:
- BrightSpring Health Divests Community Living to Sevita
- BrightSpring reports preliminary FY24 revenue $11.2B-$11.3B, consensus $11.17B
- BrightSpring Health to divest Community Living business
- BrightSpring Health price target raised to $22 from $20 at Mizuho
- BrightSpring Health price target raised to $20 from $19 at Morgan Stanley